Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19194125 | ORGANIC NANOCOMPOSITE COATING FOR PHARMACEUTICAL APPLICATIONS AND A METHOD OF FABRICATION THEREOF | April 2025 | August 2025 | Allow | 3 | 0 | 1 | No | No |
| 18308557 | NANOLIPOSOMES FOR SUSTAINED DELIVERY OF TACROLIMUS FOR TREATMENT OF ANTERIOR SEGMENT EYE DISEASES | April 2023 | October 2025 | Allow | 30 | 1 | 0 | No | No |
| 18146787 | PECTIN BASED FIRMING SYSTEM FOR ANTIAGING SKIN CARE AND MAKEUPS | December 2022 | October 2024 | Allow | 21 | 2 | 0 | No | No |
| 18064470 | HAIR STYLING COMPOSITIONS | December 2022 | April 2024 | Allow | 16 | 1 | 0 | No | No |
| 18070863 | SKIN CARE COMPOSITION AND METHOD FOR TREATING POST-ACNE MARKS | November 2022 | April 2024 | Allow | 17 | 1 | 0 | No | No |
| 18000154 | LIPOSOME CONTAINING ETHYLENEDIAMINE TETRAACETIC ACID OR SALT THEREOF AND ERIBULIN OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | November 2022 | December 2025 | Abandon | 36 | 1 | 0 | No | No |
| 17992662 | STIMULI RESPONSIVE BLOCK COPOLYMERS | November 2022 | April 2025 | Allow | 29 | 1 | 1 | No | No |
| 17926663 | SYNERGISTIC ANTI-VIRAL PHARMACEUTICAL COMPOSITION CONTAINING TARGETING NANOPARTICLES | November 2022 | February 2026 | Allow | 39 | 1 | 0 | Yes | No |
| 17985927 | Hair growth essence and its preparation method | November 2022 | May 2024 | Abandon | 18 | 1 | 1 | No | No |
| 17979312 | COSMETIC PRODUCT COMPRISING OIL DISCONTINUOUS PHASE | November 2022 | October 2024 | Abandon | 24 | 2 | 0 | No | No |
| 17977139 | Personal Care Compositions | October 2022 | January 2024 | Allow | 15 | 1 | 0 | Yes | No |
| 18049244 | METHOD FOR MAKING MODIFIED POLYVINYL ALCOHOL EMBOLIC MICROSPHERE | October 2022 | December 2023 | Allow | 13 | 1 | 0 | No | No |
| 17940746 | METFORMIN TABLET FOR RELIEVING PAIN AND REDUCING INFLAMMATION AND MANUFACTURING METHOD THEREOF | September 2022 | August 2024 | Allow | 24 | 1 | 1 | Yes | No |
| 17876611 | Implantable Medical Device for the Delivery of Bisphosphonate | July 2022 | July 2024 | Abandon | 23 | 1 | 1 | No | No |
| 17811446 | PARTIALLY PRE-GELATINIZED CASSAVA STARCH AS PHARMACEUTICAL EXCIPIENT | July 2022 | September 2024 | Allow | 26 | 2 | 0 | Yes | No |
| 17791815 | NANOBOWL-SUPPORTED DRUG-LOADED LIPOSOME, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | July 2022 | December 2025 | Allow | 41 | 2 | 0 | No | No |
| 17858484 | ORODISPERSIBLE FORMULATIONS | July 2022 | April 2025 | Abandon | 34 | 1 | 0 | No | No |
| 17808305 | HAIR-STRAIGHTENING COMPOSITIONS | June 2022 | August 2024 | Abandon | 25 | 2 | 0 | No | No |
| 17838360 | MULTI-FUNCTION HAIR CARE COMPOSITION | June 2022 | April 2024 | Allow | 22 | 2 | 0 | No | No |
| 17783744 | ESKETAMINE FORMULATIONS AND METHODS FOR PREPARATION AND STORAGE | June 2022 | February 2026 | Allow | 44 | 1 | 1 | No | No |
| 17756619 | AMLODIPINE MESYLATE MONOHYDRATE PREPARATION METHOD THEREFOR AND USE THEREOF | May 2022 | May 2025 | Allow | 36 | 1 | 0 | No | No |
| 17777800 | VETERINARY FORMULATIONS COMPRISING RAPAMYCIN AND METHODS OF USING THE SAME FOR TREATING ANIMAL DISEASE | May 2022 | December 2025 | Allow | 43 | 2 | 0 | Yes | No |
| 17742418 | LIPOSOME COMPOSITION AND PREPARATION METHOD THEREOF | May 2022 | October 2025 | Allow | 41 | 1 | 0 | No | No |
| 17697362 | Method of Combining Pigmentation Agents in Hair Dyeing and Related Products for Generating Cool Tones | March 2022 | January 2024 | Abandon | 22 | 1 | 0 | No | No |
| 17633723 | FORMULATION | February 2022 | March 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17630681 | LIPOSOMES AND USES THEREOF | January 2022 | July 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17630451 | PIGMENTS CONTAINING CELLULOSE | January 2022 | February 2025 | Abandon | 36 | 1 | 0 | No | No |
| 17619019 | SYNERGISTIC FUNGICIDAL COMPOSITION | December 2021 | July 2025 | Allow | 43 | 2 | 0 | No | No |
| 17616951 | Engineered nono-lyposomes for a targeted therapy of atherosclerosis and preparation process thereof | December 2021 | September 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17539470 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ASTHMA, PNEUMONIA, BRONCHITIS, CYSTIC FIBROSIS, PULMONARY EDEMA, INTERSTITIAL LUNG DISEASE, SARCOIDOSIS, IDIOPATHIC PULMONARY FIBROSIS, ACUTE RESPIRATORY DISTRESS SYNDROME, AND PULMONARY ARTERIAL HYPERTENSION | December 2021 | June 2025 | Allow | 42 | 4 | 1 | Yes | No |
| 17614881 | INJECTABLE COMPOSITION CONTAINING PRODRUG OF CASPASE INHIBITORS, AND PREPARATION METHOD THEREFOR | November 2021 | November 2024 | Allow | 35 | 1 | 0 | No | No |
| 17526833 | DIPIVEFRIN ORALLY DISINTEGRATING TABLET FORMULATIONS | November 2021 | July 2024 | Abandon | 32 | 0 | 1 | No | No |
| 17280379 | DOSAGE FORMS COMPRISING ACTIVE PHARMACEUTICAL INGREDIENTS | October 2021 | October 2025 | Abandon | 55 | 2 | 0 | No | No |
| 17606657 | SHAPE MEMORY POLYMER HYDROGELS FOR WOUND HEALING | October 2021 | October 2025 | Allow | 48 | 2 | 1 | No | No |
| 17604330 | BIODEGRADABLE NASAL SPLINT | October 2021 | November 2024 | Abandon | 37 | 1 | 0 | No | No |
| 17603815 | TABLET AND METHOD FOR PRODUCING TABLET | October 2021 | October 2025 | Allow | 48 | 2 | 1 | No | No |
| 17600203 | Siremadlin Succinate | September 2021 | November 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17598691 | Covalent Modification and Controlled Delivery of Mu Opioid Receptor Antagonists | September 2021 | June 2025 | Allow | 44 | 2 | 0 | Yes | No |
| 17598797 | METHODS OF IMPROVING PHARMACEUTICAL SUBSTANCE SOLUBILIZATION AND PRODUCTS THEREOF | September 2021 | January 2025 | Allow | 40 | 1 | 0 | No | No |
| 17438969 | PROCESS FOR SPRAY DRYING A GLP-1 PEPTIDE | September 2021 | September 2024 | Allow | 36 | 1 | 0 | No | No |
| 17435905 | BENZOAZEPINE COMPOUND-CONTAINING FREEZE-DRIED COMPOSITION | September 2021 | February 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17431285 | SURGICAL GLUES BASED ON MONOMERS COMPRISING A PHOSPHATE FUNCTION | August 2021 | February 2025 | Allow | 42 | 1 | 0 | No | No |
| 17431399 | SATIETY INDUCING FOOD PRODUCTS AND PREPARATION THEREOF | August 2021 | April 2025 | Allow | 44 | 2 | 1 | Yes | No |
| 17431303 | METHOD FOR SUPPRESSING COLD FLOW OF ACRYLIC PATCH | August 2021 | April 2025 | Abandon | 44 | 2 | 0 | No | No |
| 17430943 | Process for the preparation of microcapsules | August 2021 | September 2024 | Allow | 38 | 1 | 0 | No | No |
| 17425057 | ELECTROSPUN NANOFIBER-BASED DRESSINGS AND METHODS OF MANUFACTURE AND USE THEREOF | July 2021 | November 2025 | Abandon | 51 | 2 | 1 | No | No |
| 17425253 | DENTAL FLOSS FOR PREVENTING OR TREATING DENTAL CARIES AND PERIODONTAL DISEASE | July 2021 | May 2025 | Abandon | 46 | 2 | 0 | No | No |
| 17377103 | COMPOSITIONS AND METHODS FOR PREVENTION OF VIRAL INFECTIONS AND ASSOCIATED DISEASES | July 2021 | August 2024 | Abandon | 37 | 0 | 1 | No | No |
| 17419397 | ORAL ARTICLES AND METHODS OF USE | June 2021 | October 2025 | Allow | 52 | 3 | 0 | No | No |
| 17341812 | ANTIMICROBIAL and ANTI-INFLAMMATORY COMPOSITION | June 2021 | September 2025 | Abandon | 51 | 4 | 1 | No | No |
| 17296927 | CLEANSING COMPOSITION | May 2021 | December 2025 | Abandon | 55 | 3 | 0 | No | No |
| 17296244 | BIODEGRADEABLE IMPLANT COMPRISING COATED METAL ALLOY PRODUCT | May 2021 | April 2025 | Allow | 47 | 1 | 1 | No | No |
| 17245538 | SYNERGY FOR INCREASING ENERGY EXPENDITURE AND INSULIN SENSITIVITY | April 2021 | September 2025 | Abandon | 53 | 2 | 1 | No | No |
| 17290499 | Cosmetic Composition For Sustaining Luster | April 2021 | June 2025 | Allow | 49 | 3 | 0 | Yes | No |
| 17284335 | COATING COMPOSITION FOR MEDICAL IMPLANTS | April 2021 | September 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17284171 | COMPOSITIONS AND METHODS FOR ADMINISTERING ANESTHETICS | April 2021 | October 2025 | Abandon | 55 | 3 | 1 | No | No |
| 17250747 | POLYMER IMPLANTS | February 2021 | December 2024 | Allow | 45 | 2 | 0 | Yes | No |
| 17259499 | BINARY LIPID BILAYER-CONTAINING VESICLES COMPRISING EMBEDDED CYTOTOXIC AGENTS AND METHODS OF MAKING AND USING THE SAME | January 2021 | September 2024 | Allow | 45 | 2 | 0 | Yes | Yes |
| 17054037 | SAFENER | November 2020 | July 2025 | Abandon | 56 | 4 | 0 | Yes | No |
| 16322656 | COSMETIC TENSIONING COMPOSITION | February 2019 | July 2025 | Abandon | 60 | 8 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ABBAS, ABDULRAHMAN MUSTAFA.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 100.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner ABBAS, ABDULRAHMAN MUSTAFA works in Art Unit 1612 and has examined 33 patent applications in our dataset. With an allowance rate of 48.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 45 months.
Examiner ABBAS, ABDULRAHMAN MUSTAFA's allowance rate of 48.5% places them in the 11% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by ABBAS, ABDULRAHMAN MUSTAFA receive 2.00 office actions before reaching final disposition. This places the examiner in the 50% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by ABBAS, ABDULRAHMAN MUSTAFA is 45 months. This places the examiner in the 12% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +35.0% benefit to allowance rate for applications examined by ABBAS, ABDULRAHMAN MUSTAFA. This interview benefit is in the 83% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 14.3% of applications are subsequently allowed. This success rate is in the 10% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 41.7% of cases where such amendments are filed. This entry rate is in the 64% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 80.0% are granted (fully or in part). This grant rate is in the 83% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.